Global launch sequencing is entering a new era. Traditional “one-size-fits-all” approaches, often anchored in US-first strategies and milestone-driven timelines, are being challenged by increasing policy complexity, evolving evidence and HTA requirements, and rising commercial pressures.
Emerging dynamics such as Most Favored Nation (MFN)-style pricing and tighter HTA frameworks are intensifying interdependencies across markets and fundamentally reshaping how companies prioritize, and sequence launches globally.
In this roundtable discussion, our experts are joined by two senior industry leaders to explore how launch sequencing decisions are evolving in real-world settings, and how companies are responding to these shifts in practice.
Drawing on recent interviews with senior pharma and biotech leaders across the US and Europe, the discussion brings together different perspectives on how organizations are navigating trade-offs between speed, price sustainability, and long-term value in a more interconnected and uncertain environment.
Participants will learn more about:
- How global launch sequencing is structured in practice today, including governance models, market prioritization criteria, and cross-functional alignment
- Key challenges companies face, such as access timelines, and organizational complexity, and how to address them
- How launch sequencing approaches are shifting and evolving dynamics across major markets
- The implications of policy developments such as MFN-style pricing, EU JCA, and increasing pricing spillover effects on global launch strategies
- How leading organizations are adapting their commercialization models to remain agile
This webinar is free of charge. Don’t miss the opportunity to gain practical, peer-driven insights to inform decision-making and optimize global launch strategies.
Event details:
Thursday, April 30, 2026: 3:00 - 4:00 p.m. CEST | 9:00 - 10:00 a.m. EDT
